Skip navigation

Please use this identifier to cite or link to this item:
Title: The Landscape of the Anti-Kinase Activity of the IDH1 Inhibitors
Authors: Malarz, Katarzyna
Mularski, Jacek
Pacholczyk, Marcin
Musioł, Robert
Keywords: isocitrate dehydrogenase; tyrosine kinase; IDH1 inhibitor; ABL kinase; leukemia; anticancer activity
Issue Date: 2020
Citation: Cancers, Nr 12 2020
Abstract: Isocitrate dehydrogenases constitute a class of enzymes that are crucial for cellular metabolism. The overexpression or mutation of isocitrate dehydrogenases are often found in leukemias, glioblastomas, lung cancers, and ductal pancreatic cancer among others. Mutation R132H, which changes the functionality of an enzyme to produce mutagenic 2-hydroxyglutarate instead of a normal product, is particularly important in this field. A series of inhibitors were described for these enzymes of which ivosidenib was the first to be approved for treating leukemia and bile duct cancers in 2018. Here, we investigated the polypharmacological landscape of the activity for known sulfamoyl derivatives that are inhibitors, which are selective towards IDH1 R132H. These compounds appeared to be effective inhibitors of several non-receptor kinases at a similar level as imatinib and axitinib. The antiproliferative activity of these compounds against a panel of cancer cells was tested and is explained based on the relative expression levels of the investigated proteins. The multitargeted activity of these compounds makes them valuable agents against a wide range of cancers, regardless of the status of IDH1.
DOI: 10.3390/cancers12030536
ISSN: 2072-6694
Appears in Collections:Artykuły (WNŚiT)

Files in This Item:
File Description SizeFormat 
Malarz_The_Landscape.pdf1,82 MBAdobe PDFView/Open
Show full item record

Uznanie Autorstwa 3.0 Polska Creative Commons License Creative Commons